Patient Recorded Indexing Measurements

Cancer Clinical Trial

— PRIMs  

Official title:

Patient Recorded Indexing Measurements

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05899205
• Other study ID #: NL65402.068.18
• Status: Recruiting
• Start date: June 1, 2021
• Est. completion date: June 1, 2025

Study information

• Verified date: June 2023
• Source: Academisch Ziekenhuis Maastricht
• Contact: Nicole Hildebrand, M.D.
• Phone: +31 (0)43-3881584
• Email: nicole.hildebrand[@]mumc.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Rationale: One of the greatest challenges in the field of cancer treatment is cachexia, a multifactorial syndrome characterized by substantial loss of body weight (muscle and fat mass), leading to progressive functional impairment. Cancer cachexia significantly impairs quality of life and survival as well as treatment outcome. Despite its considerable relevance for the prognosis of cancer patients, the diagnosis of cachexia is problematic. The current consensus definition of cancer cachexia is based on weight loss over the last six months. In practice, this is assessed by subjective reporting by the patient, which is subject to error and bias. Novel technologies enable accurate, standardized, and objective assessment of body weight and physical activity by newly diagnosed cancer patients in the home situation. Because of the increasing implementation of neo-adjuvant treatment strategies that offer an extended time-window for the collection of these data, there is a great opportunity to use this information in risk analyses by treating physicians, optimization of pre-habilitation programs, and in the shared-decision making process with the patient. Objective: The primary objective of this study is to obtain accurate data regarding physical activity, body composition, and body weight loss over time in patients with gastric, esophageal, rectal, pancreatic, or ovarian cancer in relation to treatment outcome, adverse events (chemotoxicity and/or surgical complications), and survival. Study design: Explorative pilot study Study population: Patients between 18 and 80 years old undergoing surgical resection or neo-adjuvant chemotherapy for the treatment of gastric, esophageal, rectal, ovarian, or pancreatic cancer. Main study parameters/endpoints: Objective data acquisition on activity (three axis acceleromotion using a wrist-worn accelerometer), body weight (at home measurement with memory integrated weight scale), and body composition in relation to treatment outcome, evaluated using RECIST, adverse events, assessed via chemotoxicity and surgical complications using the Clavien-Dindo classification, and length of hospital stay in gastric, esophageal, rectal, pancreatic, and ovarian cancer patients. Secondary endpoints: To assess body weight changes and physical activity in relation to survival.

Description:

Patients requiring neo-adjuvant chemotherapy or primary surgery for pancreatic, esophageal, gastric, ovarian, or colorectal cancer will be included. Patients will undergo extensive pre-treatment screening, and then receive a weight scale for daily at-home measurements of body weight and an accelerometer for assessing physical activity. Body weight data will be collected using an electronic weight scale with integrated memory SD cards for automated autonomous storage of data (CE licensed). Physical activity will be monitored through a research grade wrist-worn accelerometer that records movement in three axes as well as body position (sedentary versus standing position). Data on frequency, intensity, and duration of activity will be collected. Activity can be summarized into light, moderate and (very) vigorous activity. Additionally, data on sedentary behavior will be collected. Monitoring plan for patients treated with chemotherapy: T0 Start of monitoring: When patients first present at the outpatient clinic, they will receive extensive physical analysis by a trained physiotherapist. The screening will consist of the following: Timed Up and Go test, Chair stand test, 2-minute walking test, hand grip strength test, steep ramp test, and short nutritional assessment procedure. This screening is already part of clinical routine and pre-operative screening for extensive abdominal surgery at the MUMC+. Additionally, the investigators will collect one blood sample. Patients will receive equipment (weight scale and accelerometer) for at home monitoring. The patient will start using the weight scale daily and wear the accelerometer continuously after screening. T1: Start of chemotherapy: During chemotherapy, the body weight and physical activity measurements will continue. Patients will use the scale once daily and the accelerometer continuously. Chemotherapy related outcomes will be recorded during routine patient contacts, including treatment toxicity, intensity, and outcome as monitored according to the Common Toxicity Criteria version 5.0 and by assessing dose index (received cumulative dose/planned cumulative dose) and time index (planned duration of therapy/actual duration of therapy). Treatment outcome will be evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST). T2: End of chemotherapy: The monitoring will continue until two weeks after chemotherapy. T3: End of monitoring (at routine follow-up by senior surgeon, usually 2-3 weeks after completion of chemotherapy). A routine CT-scan to assess the effect of the chemotherapy will be performed. Body composition analysis at the L3-level will be used to assess the cross-sectional area and radiation attenuation of skeletal muscle (SM), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and intramuscular adipose tissue. This will be done using automated segmentation. Patients will hand in all equipment to the researcher during regular follow-up. Monitoring plan for patients treated with surgery: T0 start of monitoring: When patients first present at the outpatient clinic, they will receive extensive physical analysis by a trained physiotherapist. The screening will consist of the following: Timed Up and Go test, Chair stand test, 2-minute walking test, hand grip strength analysis, steep ramp test, and short nutritional assessment procedure. This screening is already part of clinical routine and pre-operative screening for extensive abdominal surgery at the MUMC+. Additionally, the investigators will collect one blood sample. Patients will receive equipment (weight scale and accelerometer) for at home monitoring. The patient will start using the weight scale daily and wear the accelerometer continuously. T1: Hospital admission: At the day of admission, the patient will not bring the weight scale and accelerometer to the hospital. Monitoring will be paused for the length of hospital stay for primary surgery. Postoperative complications will be recorded according to the Clavien-Dindo classification. T2: Discharge from hospital: At the day of discharge after primary surgery, length of stay at the hospital will be recorded. The patient will be reminded to restart monitoring and use the weight scale daily and wear the accelerometer continuously. T3: End of monitoring: During the regular follow-up visit 2-3 weeks after discharge, monitoring will end. Patients will hand in all equipment to the researcher during the regular follow-up visit. Over the course of the oncological follow-up, a routine CT-scan will be performed. Body composition analysis at the L3-level will be used to assess the cross-sectional area and radiation attenuation of skeletal muscle (SM), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and intramuscular adipose tissue. This will be done using automated segmentation. The investigators will obtain blood samples twice during this period at T0 and just prior to incision on the day of surgery (T1) to analyse HbA1c, haemoglobin, CRP, TNF-α, interleukin-6, blood lipids, and additional parameters related to inflammation. No diagnostic procedures or treatment will be postponed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: June 1, 2025
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age = 18
• Diagnosed with gastric, esophageal, colorectal, ovarian, or pancreatic cancer
• Planned for primary surgery or neo-adjuvant chemotherapy

Exclusion Criteria:

• ASA-classification V,
• severe liver cirrhosis Child grade C,
• end stage renal disease requiring dialysis,
• severe heart disease New York Heart Association class IV,
• chronic obstructive pulmonary disease (COPD) requiring (home)oxygen therapy,
• Patients must be "mobile". They may not be bedridden or in a wheelchair.

Related Conditions & MeSH terms

• Body Weight
• Cachexia
• Cancer
• Weight, Body

Locations

Country	Name	City	State
Netherlands	Maastricht University Medical Center+	Maastricht
Netherlands	Zuyderland Medical Center	Sittard

Sponsors (3)

Lead Sponsor	Collaborator
Academisch Ziekenhuis Maastricht	Maastricht University, Zuyderland Medisch Centrum

Country where clinical trial is conducted

Netherlands, 

References & Publications (40)

Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018 Jan 18;4:17105. doi: 10.1038/nrdp.2017.105. — View Citation

Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer. 2008 May;16(5):447-51. doi: 10.1007/s00520-007-0388-7. Epub 2008 Jan 15. — View Citation

Boyle T, Lynch BM, Courneya KS, Vallance JK. Agreement between accelerometer-assessed and self-reported physical activity and sedentary time in colon cancer survivors. Support Care Cancer. 2015 Apr;23(4):1121-6. doi: 10.1007/s00520-014-2453-3. Epub 2014 Oct 11. — View Citation

Broderick JM, Ryan J, O'Donnell DM, Hussey J. A guide to assessing physical activity using accelerometry in cancer patients. Support Care Cancer. 2014 Apr;22(4):1121-30. doi: 10.1007/s00520-013-2102-2. Epub 2014 Jan 4. — View Citation

Cawley J, Maclean JC, Hammer M, Wintfeld N. Reporting error in weight and its implications for bias in economic models. Econ Hum Biol. 2015 Dec;19:27-44. doi: 10.1016/j.ehb.2015.07.001. Epub 2015 Jul 23. — View Citation

Connor Gorber S, Tremblay M, Moher D, Gorber B. A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. Obes Rev. 2007 Jul;8(4):307-26. doi: 10.1111/j.1467-789X.2007.00347.x. — View Citation

Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol. 2015 Jul;22(7):2416-23. doi: 10.1245/s10434-014-4285-2. Epub 2014 Dec 18. — View Citation

Del Fabbro E. Current and future care of patients with the cancer anorexia-cachexia syndrome. Am Soc Clin Oncol Educ Book. 2015:e229-37. doi: 10.14694/EdBook_AM.2015.35.e229. — View Citation

Delisle Nystrom C, Pomeroy J, Henriksson P, Forsum E, Ortega FB, Maddison R, Migueles JH, Lof M. Evaluation of the wrist-worn ActiGraph wGT3x-BT for estimating activity energy expenditure in preschool children. Eur J Clin Nutr. 2017 Oct;71(10):1212-1217. doi: 10.1038/ejcn.2017.114. Epub 2017 Jul 26. — View Citation

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. — View Citation

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. — View Citation

Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013 Feb;10(2):90-9. doi: 10.1038/nrclinonc.2012.209. Epub 2012 Dec 4. — View Citation

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4. — View Citation

Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y, Nishie A, Yamanaka T. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013 Oct;100(11):1523-30. doi: 10.1002/bjs.9258. — View Citation

Hsueh HY, Pita-Grisanti V, Gumpper-Fedus K, Lahooti A, Chavez-Tomar M, Schadler K, Cruz-Monserrate Z. A review of physical activity in pancreatic ductal adenocarcinoma: Epidemiology, intervention, animal models, and clinical trials. Pancreatology. 2022 Jan;22(1):98-111. doi: 10.1016/j.pan.2021.10.004. Epub 2021 Oct 26. — View Citation

Huang DD, Wang SL, Zhuang CL, Zheng BS, Lu JX, Chen FF, Zhou CJ, Shen X, Yu Z. Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis. 2015 Nov;17(11):O256-64. doi: 10.1111/codi.13067. — View Citation

Kurk S, Peeters P, Stellato R, Dorresteijn B, de Jong P, Jourdan M, Creemers GJ, Erdkamp F, de Jongh F, Kint P, Simkens L, Tanis B, Tjin-A-Ton M, Van Der Velden A, Punt C, Koopman M, May A. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):803-813. doi: 10.1002/jcsm.12436. Epub 2019 May 15. — View Citation

Latrille M, Buchs NC, Ris F, Koessler T. Physical activity programmes for patients undergoing neo-adjuvant chemoradiotherapy for rectal cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2021 Dec 23;100(51):e27754. doi: 10.1097/MD.0000000000027754. — View Citation

Lugo D, Pulido AL, Mihos CG, Issa O, Cusnir M, Horvath SA, Lin J, Santana O. The effects of physical activity on cancer prevention, treatment and prognosis: A review of the literature. Complement Ther Med. 2019 Jun;44:9-13. doi: 10.1016/j.ctim.2019.03.013. Epub 2019 Mar 20. — View Citation

McTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B, Tennant B, Vaux-Bjerke A, George SM, Troiano RP, Piercy KL; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE*. Physical Activity in Cancer Prevention and Survival: A Systematic Review. Med Sci Sports Exerc. 2019 Jun;51(6):1252-1261. doi: 10.1249/MSS.0000000000001937. — View Citation

Ninomiya G, Fujii T, Yamada S, Yabusaki N, Suzuki K, Iwata N, Kanda M, Hayashi M, Tanaka C, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. Int J Surg. 2017 Mar;39:45-51. doi: 10.1016/j.ijsu.2017.01.075. Epub 2017 Jan 18. — View Citation

Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM, Lyadov V. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology. 2015 Jan-Feb;15(1):19-24. doi: 10.1016/j.pan.2014.11.006. Epub 2014 Dec 4. — View Citation

Peddle-McIntyre CJ, Cavalheri V, Boyle T, McVeigh JA, Jeffery E, Lynch BM, Vallance JK. A Review of Accelerometer-based Activity Monitoring in Cancer Survivorship Research. Med Sci Sports Exerc. 2018 Sep;50(9):1790-1801. doi: 10.1249/MSS.0000000000001644. — View Citation

Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, Makary M, Hirose K, Edil B, Choti MA, Herman J, Cameron JL, Wolfgang CL, Pawlik TM. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012 Aug;16(8):1478-86. doi: 10.1007/s11605-012-1923-5. Epub 2012 Jun 13. — View Citation

Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009 Apr 15;15(8):2920-6. doi: 10.1158/1078-0432.CCR-08-2242. Epub 2009 Apr 7. — View Citation

Prince SA, Adamo KB, Hamel ME, Hardt J, Connor Gorber S, Tremblay M. A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. Int J Behav Nutr Phys Act. 2008 Nov 6;5:56. doi: 10.1186/1479-5868-5-56. — View Citation

Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O'Brien ME. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004 May 17;90(10):1905-11. doi: 10.1038/sj.bjc.6601781. — View Citation

Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):458-66. doi: 10.1002/jcsm.12107. Epub 2016 Mar 7. — View Citation

Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition. 2019 Nov-Dec;67-68:110539. doi: 10.1016/j.nut.2019.06.020. Epub 2019 Jun 28. — View Citation

Sealy MJ, Dechaphunkul T, van der Schans CP, Krijnen WP, Roodenburg JLN, Walker J, Jager-Wittenaar H, Baracos VE. Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. Clin Nutr. 2020 Feb;39(2):501-509. doi: 10.1016/j.clnu.2019.02.029. Epub 2019 Feb 22. — View Citation

Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug;33(8):339.e17-23. doi: 10.1016/j.urolonc.2015.01.011. Epub 2015 Jun 18. — View Citation

Shintakuya R, Uemura K, Murakami Y, Kondo N, Nakagawa N, Urabe K, Okano K, Awai K, Higaki T, Sueda T. Sarcopenia is closely associated with pancreatic exocrine insufficiency in patients with pancreatic disease. Pancreatology. 2017 Jan-Feb;17(1):70-75. doi: 10.1016/j.pan.2016.10.005. Epub 2016 Oct 11. — View Citation

Sikkens EC, Cahen DL, de Wit J, Looman CW, van Eijck C, Bruno MJ. A prospective assessment of the natural course of the exocrine pancreatic function in patients with a pancreatic head tumor. J Clin Gastroenterol. 2014 May-Jun;48(5):e43-6. doi: 10.1097/MCG.0b013e31829f56e7. — View Citation

van Dijk DP, Bakens MJ, Coolsen MM, Rensen SS, van Dam RM, Bours MJ, Weijenberg MP, Dejong CH, Olde Damink SW. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):317-326. doi: 10.1002/jcsm.12155. Epub 2016 Oct 26. — View Citation

van Dijk DPJ, Bakers FCH, Sanduleanu S, Vaes RDW, Rensen SS, Dejong CHC, Beets-Tan RGH, Olde Damink SWM. Myosteatosis predicts survival after surgery for periampullary cancer: a novel method using MRI. HPB (Oxford). 2018 Aug;20(8):715-720. doi: 10.1016/j.hpb.2018.02.378. Epub 2018 Mar 5. — View Citation

van Dijk DPJ, Krill M, Farshidfar F, Li T, Rensen SS, Olde Damink SWM, Dixon E, Sutherland FR, Ball CG, Mazurak VC, Baracos VE, Bathe OF. Host phenotype is associated with reduced survival independent of tumour biology in patients with colorectal liver metastases. J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):123-130. doi: 10.1002/jcsm.12358. Epub 2018 Oct 31. — View Citation

Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013 Jun;21(6):1569-77. doi: 10.1007/s00520-012-1697-z. Epub 2013 Jan 13. — View Citation

Wang SL, Zhuang CL, Huang DD, Pang WY, Lou N, Chen FF, Zhou CJ, Shen X, Yu Z. Sarcopenia Adversely Impacts Postoperative Clinical Outcomes Following Gastrectomy in Patients with Gastric Cancer: A Prospective Study. Ann Surg Oncol. 2016 Feb;23(2):556-64. doi: 10.1245/s10434-015-4887-3. Epub 2015 Dec 14. — View Citation

West MA, van Dijk DPJ, Gleadowe F, Reeves T, Primrose JN, Abu Hilal M, Edwards MR, Jack S, Rensen SSS, Grocott MPW, Levett DZH, Olde Damink SWM. Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery. J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):860-871. doi: 10.1002/jcsm.12433. Epub 2019 May 21. — View Citation

Yip C, Goh V, Davies A, Gossage J, Mitchell-Hay R, Hynes O, Maisey N, Ross P, Gaya A, Landau DB, Cook GJ, Griffin N, Mason R. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol. 2014 May;24(5):998-1005. doi: 10.1007/s00330-014-3110-4. Epub 2014 Feb 18. — View Citation

* Note: There are 40 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Physical activity	Accelerometry data on three axes	through treatment, average of 5-14 weeks
Primary	Body weight	At home measurement with memory integrated weight scale	through treatment, average of 5-14 weeks
Primary	Treatment outcome	Treatment outcome will be evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST)	through treatment, average of 5-14 weeks
Primary	Change in body composition (adipose tissue surface and muscular tissue surface)	Automated segmentation of body composition on the L3 level of abdominal CT-scans	through treatment, average of 5-14 weeks
Primary	Number of treatment-related adverse events as assessed by CTCAE v5.0	Chemotoxicity according to Common Toxicity Criteria v5.0	through treatment, average of 5-14 weeks
Primary	Postoperative complications	Postoperative complications rated according to Clavien-Dindo classification	30 days postoperatively
Secondary	Functional mobility/muscle strength	Timed up and go test (in sec)	2-4 weeks before treatment start
Secondary	Functional mobility	2 minute walking test (in m)	2-4 weeks before treatment start
Secondary	Muscle strength	Grip strength analysis (in kg)	2-4 weeks before treatment start
Secondary	Aerobic capacity	Steep ramp test (in W)	2-4 weeks before treatment start
Secondary	Nutritional status	Weight loss before diagnosis	2-4 weeks before treatment start
Secondary	Overall survival	Overall and recurrence free survival	Up to 5 years after completion
Secondary	Recurrence free survival	Recurrence free survival	Up to 5 years after completion